Library

Place of publication: physical and rehabilitation medicine, medical rehabilitation / vol. 6, No. 4, 2024

Autonomous non -profit organization "Clinical Institute of the Brain", Berezovsky, Russia

Annotation
justification. The study of the use of pharmacotherapy as an adjuvant component of rehabilitation of patients with acute cerebral failure is of scientific and practical interest.

The purpose of the study is to study the effectiveness and safety of consistent therapy with the drugs of the group for the treatment of diseases of the nervous system in a comprehensive rehabilitation program for patients with acute cerebral failure in the aspect of the impact on the severity of emotional and cognitive disorders, mobility, the severity of the syndrome of the consequences of intensive care and the implementation of their rehabilitation potential.

Materials and methods . The randomized intervention prospective study of 60 patients with acute cerebral failure, divided into 2 groups, included five visits. Patients of the main group received standard therapy and the drug ethyl hydroxypyridine serpentine (intravenously 500 mg/day, 10 days),
then ethylmethylhydroxypirinate of the forte 250 (1 tablet 3 times/day, 8 weeks); Patients of the control group during the same period received only standard therapy.
Results. Both groups noted a comparable improvement in cognitive functions on the Mosa scale (p <0.001). The statistically significant superiority in reducing the level of anxiety on the HADS scale is shown on visit 4 in the main group compared to the control: 2 [1; 4] and 5 [2.25; 7] points, respectively (p <0.01). A significant increase in the Rivermide index in both groups at all stages of the study (p <0.001) was determined in excess of the value of the median in the main group by 3 points compared to the control for visit 5 (p <0.001). The tendency to the superiority of the main group over the control in terms of the life of the rehabilitation routing scale (SRM; p = 0.053) was combined with statistically significantly smaller number of disabled patients (≥3 points for scraps) than in the control group, to visits 5 (χ2 Yates = 4; P = 0.045). In patients of both groups, the consequences syndrome were determined by the intensive care therapy of a slight severity with a tendency to reduce the number of patients from the 3rd to the 5th visit in the main group compared to the control (χ2 Yates = 3.491; p = 0.062). At the visit 5, the relationship of indicators on the scrap scale and the Rivermide index in patients of both groups (P <0.05) and the SPRM and MOCA scales in patients of the main group (P <0.01) is established. No undesirable phenomena for the period of research were not noted.
Conclusion. The positive effect of sequential therapy of the group’s drugs for the treatment of diseases of the nervous system in the complex rehabilitation program of patients with acute cerebral deficiency on the state of their emotional-cognitive status, the degree of disability, mobility, the severity of the consequences of intensive care and rehabilitation prognosis was demonstrated. A high degree of safety of the study scheme of therapy has been proved.
Key words: acute cerebral failure; ethylmethylhydroxypyridine succinate; Hads; Moca; MRC; Rivermide index; Scrap; intensive care syndrome; Pits; Rehabilitation potential.
How to quote:
Belkin V.A., Vasilchenko I.E., Belkin A.A. The dynamics of domains of emotional-cognitive and motor disorders in the structure of PIT syndrome
in patients who have undergone acute cerebral failure //

Place of publication:
Bulletin of Ophthalmology, 2024, T.140, No. 4

Summary:
many key aspects of neurodegeneration of ganglion cells of the retina (GKS) with glaucoma are focused on mitochondrial dysfunction. Understanding the mechanisms and the relationships between structural and functional changes in mitochondria would be useful for development related to the mitochondria of the therapeutic strategy for the protection of GCS from glaucomone neurodegeneration. The purpose of the study. To find out the degree of severity of mitochondrial dysfunction in patients with primary open -angle glaucoma (POUG) and evaluate the possibility of stabilizing the glaucomic process by improving the functional activity of mitochondria, their energy -forming function against the background of therapy with Mexidol and Mexol Forte 250. Material and methods. The study was involved in 80 patients with a developed stage with compensated intraocular pressure and 20 healthy volunteers. The degree of severity of mitochondrial dysfunction was determined by the level of activity of mitochondrial enzymes: succinate dehydrogenase (SDH) and α-glycerophosphatedehydrogenase (α-GFDD)-in peripheral blood lymphocytes during cytochemical examination and cytomomorphodenxitis. Patients of the main group received consistent therapy with Mexidol with the following scheme: Mexoling a solution for intravenous and intramuscular administration of 50 mg/ml 300 mg per day intramuscularly 1 time per day for 14 days, followed by the purpose of Mexol Forte 250 1 tablet 3 times per 3 times aim Day for 56 days. Stabilization of glaucoma of optical neuropathy against the background of treatment was evaluated using a complex of perimetric, electrophysiological, structural-topographic methods in a period of 14, 56 and 90 days. Results. Against the background of consistent therapy, patients of the main group revealed a significant increase in the activity of mitochondrial enzymes compared with the initial level after 14 and 56 days with smooth regression by the end of the observation period (after 90 days), which was accompanied by an increase in the amount of mitochondria, an increase in their optical density in cytomorphodensitometry. Improving the enzymatic activity of mitochondrial enzymes in a period of 14 and 56 days was accompanied by a positive dynamics of structural-functional retinal indicators according to static perimetry, optical coherent tomography and a complex of electro-physiological studies. Conclusion. The data obtained can be used to optimize therapy for therapy by a decrease in mitochondrial dysfunction and stabilizing the glaucoma of optical neuroopticopathy. Keywords: primary open-angle glaucoma, mitochondrial dysfunction, succinate dehydrogenase, α-glycerophospatdehydrogenase, cytomomorphodenxometry, mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2024, T. 124, No. 11

Summary:
the article is devoted to an important problem of diagnosis and treatment of children with autonomic dysfunction syndrome (SVD). Information about the evolution of views on the pathogenesis of this state is given. The issues of pathogenesis, classification and clinical manifestations of SVD in patients in childhood and adolescence are covered in detail. The high efficiency of the use of the drug Mexidol was demonstrated in the complex correction and prevention of the manifestations of the SVD, as well as the accompanying psychoneurological disorders in children and adolescents. Key words: vegetative disorders, autonomic dysfunction syndrome, children, Mexidol.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2024, T. 124, No. 10

Summary:
The article provides new information about the development of oxidative stress (OS) in chronic headaches (GB). The main biochemical characteristics of the OS are presented. Changes in MRI spectroscopy and biochemical markers are described, confirming the development of OS in migraine. The lack of significant differences in the indicators of the OS for migraine without aura and with aura is emphasized. The pathophysiological differences of migraine and chronic GB of stress are shown, at which the OS is not detected. Possible activation is discussed with the OS TRPA1 and calcitonin-genius peptide, which provokes migraine attacks. The directions of drug correction of the OS in chronic headache are considered. Key words: headache, migraine, chronic headache of tension, oxidative stress, antioxidants.

Place of publication:
cardiology and cardiovascular surgery, 2024, T. 17, No. 5

Summary:
Review of literature is dedicated to the effects of the drug Ethylmethylhydroxypyridine of succinate (reference drug - Mexidol) in patients with arterial hypertension. The analysis of 44 sources of domestic and foreign literature showed a more effective achievement of the target values ​​of blood pressure, the prevention of the development of severe complications with hypertensive crises in patients who received therapy with Mexidol. Evidence of the positive influence of cytoprotective therapy on the state of the left ventricle, the vascular wall is considered. The results of large studies are presented that demonstrate the effective correction of cognitive brain dysfunction using Mexidol. The role of the drug in the stabilization of biochemical processes, including lipid oxidation, metabolism and cholesterol, which causes the playotropic effects of Mexidol in patients with arterial hypertension, is emphasized. Keywords: arterial hypertension, endothelial dysfunction, the stiffness of the vascular wall, lipid oxidation, myocardial ducaming, cognitive impairment, ethylmethylhydroxypyridine, mexidol.

Place of publication: Polyclinic Journal / No. 5, 2023

The demographic situation of recent decades is characterized by an increase in the number of elderly and senile people, for which, due to age -related physiological characteristics, the development of chronic brain ischemia (Khim) is characteristic. Currently, Khim is 60–75% of all cerebrovascular diseases.
Ichechemic strokes in most cases develop against the background of chemical and are a factor leading to the growth of focal and diffuse ischemic or ischemic-depths of the brain that aggravate the course of chemical and accelerating the development of dementia in patients. With ischemia, there is a sharp increase in oxidative processes, which, in combination with the insufficiency of the antioxidant protection system, leads to oxidative stress. It is pathogenetically explainable to include antioxidant drugs in the therapy diagram, one of the bright representatives of which is the drug Mexidol with a convincing evidence base.
If you do not carry out treatment and not eliminate the excess of active forms of oxygen generated by ischemia, the cascade of reactions that cause chaotic (necrosis) or programmable (apoptosis) cell death is activated. The successful solution to this problem is feasible when providing medical workers with the necessary medical information.

Keywords: chronic brain ischemia, aging, elderly, senile age, oxidative stress, antioxidant effect, neuroprotection, Mexidol

Place of publication: cardiology and cardiovascular surgery / t. 16, No. 6, 2023

FGAOU in Russian University of Friendship of Peoples named after Patrice Lumumba ", Moscow, Russia

Resume

The purpose of the study. To study the influence of Mexidol in the composition of complex therapy on the perception of life by a patient with heart failure (SN).

Material and methods. An open randomized study included 60 comorbide patients with coronary heart disease (coronary heart disease) and stable chronic heart failure (COL) with cognitive impairment (KN) ≤24 points on the Montreal scale of cognitive function assessment (MOCA). The average age of patients was 73.4 ± 8.6 years, 53% - male, the average fraction of the left ventricle is 43.5 ± 10.6%. 30 patients were included in the standard therapy group with the additional prescription of Mexidol (500 mg intravenously drip 1 time per day for 14 days, then 250 mg 3 times a day 8 weeks) and 30 patients in a standard therapy group. Initially and at the end of the study, an assessment of the perception of life was carried out. The survey included 4 main areas: (1) The relative importance of the goals associated with the disease, (2) problems associated with life with heart failure (CH) and taking medications for CH, (3) decision -making process related to drugs for CH, and (4) awareness and fears for available drugs for SH.
Results. The main problems associated with life with SN and the use of drugs from SN all patients, regardless of the treatment group, initially and after 10 weeks of therapy noted the effectiveness of treatment in a decrease in the symptoms of SN, in a decrease in the number of hospitalizations for SN and mortality. Other problems most urgent for patients were shortness of breath, swelling and fatigue, followed by anxiety about the disease, the need to take a large number of drugs, and the inability to do what they wanted. Lastness, patients were disturbed by depression, the inability to work, the need to help relatives, the cost of drugs and the fight against side effects of drugs. The beneficial influence of Mexidol in complex therapy on the patient’s perception with SN is shown. Improving the cognitive status of the patient, against the background of Mexidol treatment, helps to rethink the main treatment goals for more global - the effectiveness of the drug regarding a decrease in mortality, the number of hospitalizations and symptoms of SN, a decrease in the number of factors limiting the life of edema and breaths, and as a result, an increase in the physical activity of the patient. The only limiting factor is the need for a daily use of a large number of drugs and the desire to reduce their number.
Conclusion. There is a discrepancy between patient priorities and awareness of optimal drug therapy, which proved its effectiveness. Patients are poorly familiar with therapy of CH, and those who are familiar are concerned about her safety and efficiency. Long -term sequential therapy with Mexol with the addition of standard therapy in patients with chronic heart failure of the II - III functional class (according to NYHA classification) with moderate disorders of cognitive status, in addition to a reliable improvement in cognitive status and quality parameters, favorably affects the perception of life with heart failure.

Key words: heart failure, cognitive status, quality of life, Mexidol, perception of life.

Information about the authors:
Tolkacheva V.V. -https://orcid.org/0000-0001-6847-8797
Karapetyan L.V. -https://orcid.org/0000-0002-6697-2393
Khutsishvili N.I. -https://orcid.org/0009-0009-2669-8092
Galochkin S.A. -https://orcid.org/0000-0001-7370-8606
Kazamedov E.R. -https://orcid.org/0000-0002-6274-8933
Kobalava Zh.D. -https://orcid.org/0000-0002-5873-1768
Author responsible for correspondence: Tolkacheva V.V. -E-mail: tolkacheva-vv@rudn.ru

How to quote:
Tolkacheva V.V., Karapetyan L.V., Khutsishvili N.I., Galochkin S.A., Kazakhmadov E.R., Kobalava Zh.D. The influence of Mexidol in the composition of complex therapy on the perception of life by a patient with heart failure, cardiology and cardiovascular surgery. 2023; 16 (6): 642–651. https://doi.org/10.17116/kardio202316061642

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 12

Summary:
Purpose of the study. To study the effect of ethyl-hydroxypyridine of the succinate (EMGPS) on the anti-Bolar effect of the non-election inhibitor of cyclooxygenase (COO) of the sodium diclofenac and selective chief-2 ethrioxib inhibitor on the models of acute visceral and somatic pain and evaluate the possibility of using EMGPS in combination with the inhibitors of the TSU for the reduction their doses with the preservation of anti -Bolar efficiency . Material and methods. The effect of EMGPS was studied with a single oral effect on anti-Bolar effects of non-steroidal anti-inflammatory drugs (NSAIDs): a non-melting inhibitor of the diclofenac sodium and selective TSOG-2-2 etrica inhibitor-on the models of acute visceral (vinegar croching test) and somatic pains (formalin tests the one Hyperalgesia with inflammation) in an experiment on mice and rats. Results. On the model of acute visceral pain in EMGPS mice (25–100 mg/kg) does not have a significant effect on its severity, but enhances the anti -Bolea effect of sodium diclofenac (0.5 mg/kg) and ethricoxib (1 mg/kg). In the formalin test in rats that simulates pain during operational cuts (injury), EMGPS (25 mg/kg) increases the severity of the anti -folly action of TSOG inhibitors (1 mg/kg) primarily due to a decrease in pain in the acute phase, due to the effect of formalin on afferent neurons . On the model of mechanical hyperalgesia in rats caused by exudative inflammation after injection of the Karraginan solution in the paw, the EMGPS enhances the effect of diclofenac to a greater extent than ethricoxib. Conclusion. The data obtained indicate the appropriateness of clinical study of the use of EMGPS in combination with NSAIDs for visceral and somatic pain in order to evaluate its ability to increase the therapeutic effect of NSAIDs. Keywords: ethylmethylhydroxypyridine succinate, non -steroidal anti -inflammatory drugs, visceral pain, somatic pain, mouse, rats.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2022, T. 122, No. 8, Issue. 2

Summary:
Purpose of the study. The study of the role of oxidative stress in the development of disorders that occur with hemorrhagic stroke (GI), and the assessment of the influence of Mexidol on neurological and cognitive disorders with the analysis of the relationship of therapeutic effects of the drug with its antioxidant effect. Material and methods. The study was carried out on sexually mature out-and-aids weighing 260–280 g. The Gi model was created by destruction of brain tissue in the Capsula Interna with the introduction of blood damage to the place. On the 1st, 7th and 14th day after the modeling of GI in rats, death, neurological deficit (McGrow scale, a rotating rod, TVS), convulsive syndrome, violation of cognitive functions were recorded, a quantitative analysis of the indicators of oxidative stress with the assessment of TBK-active (thiobarbituric acid - TBK) products in blood plasma and homogenates of the cortex of the brain of rats. Mexidol was introduced after surgery in the first 3 days at a dose of 150 mg/kg intra-abdominal, then (from 4 to 14 days)-75 mg/kg inward. Results. Mexol in rats with GI significantly increases survival, reduces the severity of the neurological deficit on the McGROW scale (manners, paresis of 1-4 limbs, paralysis of the lower extremities, lateral position), eliminates convulsive attacks, restores violation of movement coordination (TVS) and improves training processes and improves training processes and improves learning processes and improves memory. Mexidol normalizes the concentrations of TBK-active products in the blood of animals and homogenes of the cortex of the brain of rats 1 and 7 days after the GI. Conclusion. The data obtained indicate the role of oxidative stress in the development of violations with the GI and the ability of Mexidol to weaken the neurological deficit, convulsive manifestations and cognitive disorders for GI, which limits the manifestations of oxidative stress. All this substantiates the significance of the use of Mexidol in patients with GI and determines the features of its therapeutic effects. Key words: hemorrhagic stroke, intracerebral hematoma, oxidative stress, Mexidol, neurological deficit, convulsions, cognitive disorders.

Place of publication: a journal of neurology and psychiatry named after S.S. Korsakova / vol. 120, No. 1, 2020

Resume

The purpose of the study . Studying the ability of the drug Mexidol to induce cerebral mitochondriogenesis in the brain of young and aging rats.
Material and methods. In the cerebral cortex of young (3 months; n = 216) and aging (6, 9, 12 and 15 months; n = 168), outbred rats by Western-Blot Analysis, the level of expression of cerebral mitochondriogenesis protein-markers with course use of Mexidol (20, 40, 100 mg/kg; 20 days; intra-abdominal).
Results. For the first time, it was shown that the exchange rate of Mexidol in doses of 40 and 100 mg/kg is accompanied by a dose-dependent induction of SUCNR1 sucnr1 and mitochondrial biogenesis proteins: PGC-1α transcriptional coactivator, transcription factors (NRF1, TFAM), catalytic subunits of respiratory enzymes (NDUFV2, SDHA, CYT B, COX2) and ATP-syntase (ATP5A) in the cerebral cortex of outbred rats of young and aging age. Mexol-dependent oven-sequences of subunits of mitochondrial enzymes and PGC-1α are noted only with the course use of the drug.
Conclusion. The data obtained indicate the ability of Mexidol to induce cerebral mitochondriogenesis and eliminate mitochondrial dysfunction in young and aging animals and, thus, influence one of the key pathogenetic links in the development of disorders during aging and neurodegenerative diseases.

Keywords: aging, mitochondrial dysfunction, Mexidol, succinate receptor, cerebral mitochondria-
genesis, transcription coactivator PGC-1α

Information about the authors:
Kirova Yu.I. -https://orcid.org/0000-0002-2436-3661; E-mail: Bioenerg@mail.ru
Shakova F.M. -https://orcid.org/0000-0002-0494-2500; E-mail: shakova.fatima@yandex.ru
Germanova E.L. -https://orcid.org/0000-0003-1191-8477; E-mail: Elgerm@mail.ru
Romanova G.A. -https://orcid.org/0000-0003-0090-351x; E-mail: romanovaga@mail.ru
Voronina T.A. -https://orcid.org/0000-0001-7065-469x; voroninata38@gmail.com

How to quote:
Kirova Yu.I., Shakova F.M., Germanova E.L., Romanova G.A., Voronina T.A. The influence of Mexidol on cerebral mitochondrio-
nonse at a young age and in aging. Journal of neurology and psychiatry named after S.S. Korsakova. 2020; 120 (1): 55-62. https://doi.org/10.17116/
jnevro202012001155

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 4

Summary:
Purpose of the study. Studying the influence of Mexidol on cognitive and motor functions disturbed during aging, the threshold of convulsive reaction, body weight and life expectancy in the old rat smams of the Vistar line. Material and methods. In a long experiment, a violation of cognitive functions (a test of conditional reflex of passive avoidance), motor disorders (tests of a rotating rod and pulling on the crossbar), a convulsive threshold (a test of subcutaneous administration of the pentilentetrazole), an animal mass and life expectancy were evaluated in a long experiment. Mexidol in the form of a 0.15% solution that replaced drinking water, rats received 2 courses of 2 months: at the age of 18-20 and 22-24 months. The dose of Mexidol consumed by the rat was 40–75 mg/kg/day. Results. Mexol in the old rat smams of the Vistar line with prolonged course use improves training, preservation and reproduction of a memorable trace in the test of conditional reflex of passive avoidance, increases the convulsive threshold and improves muscle tone and coordination of movements disturbed during aging, and increases life expectancy. The use of Mexidol allows us to prevent a significant increase in body weight, characteristic of aging. Conclusion. Mexidol reduces the severity of the cognitive and neurological deficiency that occurs during aging in the rats of the Vistar line, increases the threshold of convulsive reaction and increases life expectancy, which is determined by its ability to influence mitochondrioogenesis and antioxidant properties. Keywords: aging, Mexidol, life expectancy, memory violation, neurological deficit, convulsive threshold.

Place of publication:
Journal of Neurology and Psychiatry, 5, 2018

Summary:
Purpose of the study. To study the influence of the original domestic drug Mexidol on the expression of the transcription factor NRF2 in the cores of the cells of the frontal cerebral cortex with one -way occlusion of the general carotid artery. Material and methods. The work was done on 64 sexually mature rats of the Vistar line. The expression of NRF2 was determined by the immunohymic method. Results and conclusion. A single intra -Brushyne administration of Mexidol per 1 kg of body weight of the animal and its course oral administration per 1 kg of mass 3 times a day for 14 days did not affect the expression of the NRF2 factor. Unilateral occlusion of the general carotid artery increased the expression of NRF2 after 4 hours and on the 5th day after modeling occlusion. The oral administration of 100 mg of Mexidol per 1 kg of mass 3 times a day for 14 days before and after modeling ischemia increased the expression of NRF2 after 4 hours and on the 12th day compared to the norm indicators, as well as after 4 hours and on the 12th A day compared with the values ​​of the control of occlusion. Thus, it was established that Mexidol increases the expression of NRF2 in the frontal cortex of the rats of rats not in normal conditions, but with unilateral occlusion of the general carotid artery. Keywords: Mexidol, NRF2, ethylmethylhydroxypyridine succinate, ischemia, occlusion of the general carotid artery.

Place of publication:
Journal of Neurology and Psychiatry, 10, 2017

Summary:
Purpose of the study. To study the influence of Mexidol (ethylmethylhydroxypyridine of succinate) on the expression of the factor induced by hypoxia (HIF-1α), in the bark of the frontal lobe of the large hemispheres of the brain during its ischemia. Material and methods . The work was done on 64 sexually mature rats of the Vistar line. The expression of HIF-1α was determined immunohymic chemically. Results and discussion. It was established that a single intra-Brush administration of Mexidol at a dose of 120 mg/kg of mass and its course oral administration at a dose of 100 mg/kg of mass 3 times a day for 14 days does not affect the expression of the HIF-1α factor. Unilateral occlusion of the general carotid artery increases the expression of HIF-1α after 4 hours from the moment of occlusion. The oral introduction of Mexidol at a dose of 100 mg/kg of mass 3 times a day for 14 days before and after ischemia, increases the expression of HIF-1α after 4 and 12 hours compared with the norms of the norm on the 5th day compared to the values ​​of occlusion control. Thus, it was established that Mexidol increases the expression of HIF-1α in the frontal cortex of the rats of rats not in normal conditions, but with unilateral occlusion of the general carotid artery.

Place of publication:
neurology, neuropsychiatry, psychosomatics, 2017, No. 9

Summary:
The purpose of the study is a comprehensive assessment by means of pharmacinformation profiling of all possible effects of mexidol molecules, alfoseta choline, piracetam, glycine, semax in accordance with anatomical and therapy-chemical classification. Material and methods. Hemoreactomic, pharmacinformation and geronto -informational analyzes of the properties of molecules are based on a chemorectic methodology. For chemoreactic analysis, information from the databases Pubchem, HMDB and String was used; For pharmacinformation analysis - information from the international classification of ATX and a combined data selection from the TTD (Therapeutic Target Database), Supertarget, Matador (Manually Annoted Targets and Drugs Online Resource) and PDTD (Potential Drugs Database); For gerontoinformation analysis, data on the heroroprotective action of individual substances from the Pubchem database and the literature on Heroproteus from the Pubmed base, collected through the system of artificial intelligence. Results and discussion. Mexidol is characterized by a maximum set of positive effects (a drug for the treatment of central nervous system diseases, cardiovascular pathology, metabolic disorders, which has anti-inflammatory and anti-infectious properties, etc.). Mexidol and glycine predict the smallest frequencies of such side effects as itching, constipation, paresthesia, vomiting, etc. Geronto -information assessments of changes in the life expectancy of model organisms showed that Mexidol helps to increase the average life expectancy of C. Elegans (by 22.7 ± 10%) , Drosophiles (by 14.4 ± 15%) and mice (by 14.6 ± 3%, control drugs - not more than 6.1%). Conclusion. The results of the study indicate the high potential of Mexidol for use as a hero of the Heroprotector.

Place of publication:
a journal of neurology and psychiatry, 1, 2017; Ext. 2

Summary:
Purpose of the study. Comparative chemorectic analysis of the Mexidol molecule (ethylmethylhydroxypyridine succinate) with control molecules (alpha alphascerate, piracetam, glycine, semax). Material and methods . Comparisons of the chemical structure of Mexidol with molecules in the database of human metabolism and molecules in the databases of drugs. More than 40,000 compounds given in the HMDB (Human Metabolome Database) were used as a human metabolism. Results and conclusion. Hemorestom analysis showed that Mexidol can be an agonist of acetylcholine and gamut-a receptors; anti -inflammatory agent, the effects of which occur due to inhibiting the synthesis of pro -inflammatory prostaglandins; neuroprotective agent with neurotrophic properties; coagulation inhibitor; sugar -lowering and hyalipidemic agents. Mexol molecules are distinguished by a more pronounced safety profile (less impact on serotonin, dopamine and adrenergic receptors, a lower degree of interaction with potassium potatoes, Mao enzymes and p450 cytochromas). The results of modeling allow at the molecular level to clarify the mechanism of action of the Mexidol molecule.

Place of publication:
Journal of Neurology and Psychiatry, 8, 2014

Summary:
The purpose of the study is to study the penetration of Mexidol through the hematoencephalic barrier (GEB) in different parts of the brain and mitochondria of cells. Material and methods. Used the drug Mexol LLC NPK Pharmasoft (Russia). They studied the penetration of large hemispheres, cerebellum, thalamus and oblong brain into the fabric and the distribution between mitochondrial and cytoplasmic fractions of nerve cells. The concentration of Mexidol in the blood plasma and brain tissue was analyzed by the method of highly effective liquid chromatography. Results and conclusion. It was established that Mexidol penetrates through the GEB into different parts of the brain of rats. Its greatest concentration is determined in the fabric of the bark of large hemispheres. Inside the nerve cells of Mexidol is found both in the cytoplasmic and mitochondrial fractions. Keywords: Mexidol, Pharmacokinetics, Hematoencephalic Barrier, Big Hses, Mozheschok, Thalamus, Minuted Brain, Mitochondria, Highly Effective Liquid Chromatography.